Clinical Trial

A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is an open-label, multicenter, non-randomized Phase I clinical study with dose-escalation and expansion cohorts, designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of SI-B036 bispecific antibody injection in patients with locally advanced or metastatic gastrointestinal tumors and other solid tumors.
Protocol Amendment History 1 change
notable Enrollment reduced: 16 -> 10 participants 2026-07-17
Trial Details
NCT Number NCT07678970
Lead Sponsor Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Conditions Gastrointestinal Tumor, Solid Tumor
Enrollment 10 participants
Start Date 2026-07
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-16